Together with evidence that inhibiting Rac1, an upstream activator of PAK, reduces the severity of pancreatitis, these results suggest that PAK2 may be a promising therapeutic target for addressing pancreatitis-related pathophysiology in pancreatic acinar cells. The gene discussed is RAC1; the disease is pancreatitis.